{"analyses":[{"ciLowerLimit":"0.606","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.198","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3580","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.85","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.9","upperLimit":"52.9","value":"40.9"},{"groupId":"OG001","lowerLimit":"27.6","upperLimit":"47.3","value":"38.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Overall survival was defined as the date of randomization to the date of death by any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"OG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"OG001","title":"gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days","title":"Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)","type":"SECONDARY","unitOfMeasure":"Months"}